These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 33094319)

  • 1. CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy.
    Willier S; Rothämel P; Hastreiter M; Wilhelm J; Stenger D; Blaeschke F; Rohlfs M; Kaeuferle T; Schmid I; Albert MH; Binder V; Subklewe M; Klein C; Feuchtinger T
    Blood; 2021 Feb; 137(8):1037-1049. PubMed ID: 33094319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
    Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
    Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients.
    Ngai LL; Ma CY; Maguire O; Do AD; Robert A; Logan AC; Griffiths EA; Nemeth MJ; Green C; Pourmohamad T; van Kuijk BJ; Snel AN; Kwidama ZW; Venniker-Punt B; Cooper J; Manz MG; Gjertsen BT; Smit L; Ossenkoppele GJ; Janssen JJWM; Cloos J; Sumiyoshi T
    Eur J Haematol; 2021 Sep; 107(3):343-353. PubMed ID: 34053123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia.
    Morsink LM; Walter RB; Ossenkoppele GJ
    Blood Rev; 2019 Mar; 34():26-33. PubMed ID: 30401586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia.
    Zheng B; Yu SF; Del Rosario G; Leong SR; Lee GY; Vij R; Chiu C; Liang WC; Wu Y; Chalouni C; Sadowsky J; Clark V; Hendricks A; Poon KA; Chu W; Pillow T; Schutten MM; Flygare J; Polson AG
    Clin Cancer Res; 2019 Feb; 25(4):1358-1368. PubMed ID: 29959143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CD19 CAR T Cells That Secrete a Biparatopic Anti-CLEC12A Bridging Protein Have Potent Activity Against Highly Aggressive Acute Myeloid Leukemia
    Rennert PD; Dufort FJ; Su L; Sanford T; Birt A; Wu L; Lobb RR; Ambrose C
    Mol Cancer Ther; 2021 Oct; 20(10):2071-2081. PubMed ID: 34253594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of IL-12Rβ2 in CD33(+)CD38(+) pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RγC-deficient mice.
    Ferretti E; Montagna D; Di Carlo E; Cocco C; Ribatti D; Ognio E; Sorrentino C; Lisini D; Bertaina A; Locatelli F; Pistoia V; Airoldi I
    Leukemia; 2012 Feb; 26(2):225-35. PubMed ID: 21844875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.
    Liu Y; Wang S; Schubert ML; Lauk A; Yao H; Blank MF; Cui C; Janssen M; Schmidt C; Göllner S; Kleist C; Zhou F; Rahfeld JU; Sauer T; Schmitt M; Müller-Tidow C
    Int J Cancer; 2022 Apr; 150(7):1141-1155. PubMed ID: 34766343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia.
    Kim MY; Yu KR; Kenderian SS; Ruella M; Chen S; Shin TH; Aljanahi AA; Schreeder D; Klichinsky M; Shestova O; Kozlowski MS; Cummins KD; Shan X; Shestov M; Bagg A; Morrissette JJD; Sekhri P; Lazzarotto CR; Calvo KR; Kuhns DB; Donahue RE; Behbehani GK; Tsai SQ; Dunbar CE; Gill S
    Cell; 2018 May; 173(6):1439-1453.e19. PubMed ID: 29856956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells.
    Arvindam US; van Hauten PMM; Schirm D; Schaap N; Hobo W; Blazar BR; Vallera DA; Dolstra H; Felices M; Miller JS
    Leukemia; 2021 Jun; 35(6):1586-1596. PubMed ID: 33097838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia.
    Pollard JA; Alonzo TA; Gerbing RB; Woods WG; Lange BJ; Sweetser DA; Radich JP; Bernstein ID; Meshinchi S
    Blood; 2006 Oct; 108(8):2764-9. PubMed ID: 16809615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.
    Herrmann H; Sadovnik I; Eisenwort G; Rülicke T; Blatt K; Herndlhofer S; Willmann M; Stefanzl G; Baumgartner S; Greiner G; Schulenburg A; Mueller N; Rabitsch W; Bilban M; Hoermann G; Streubel B; Vallera DA; Sperr WR; Valent P
    Blood Adv; 2020 Oct; 4(20):5118-5132. PubMed ID: 33085758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.
    Minagawa K; Jamil MO; Al-Obaidi M; Pereboeva L; Salzman D; Erba HP; Lamb LS; Bhatia R; Mineishi S; Di Stasi A
    PLoS One; 2016; 11(12):e0166891. PubMed ID: 27907031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FLT3 Internal Tandem Duplication Mutation, cMPL and CD34 Expressions Predict Low Survival in Acute Myeloid Leukemia Patients.
    Ebrahim EK; Assem MM; Amin AI; Kamel MM; El Meligui YM; Metwally AM
    Ann Clin Lab Sci; 2016 Dec; 46(6):592-600. PubMed ID: 27993871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.
    Krupka C; Kufer P; Kischel R; Zugmaier G; Bögeholz J; Köhnke T; Lichtenegger FS; Schneider S; Metzeler KH; Fiegl M; Spiekermann K; Baeuerle PA; Hiddemann W; Riethmüller G; Subklewe M
    Blood; 2014 Jan; 123(3):356-65. PubMed ID: 24300852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL.
    Mehta NK; Pfluegler M; Meetze K; Li B; Sindel I; Vogt F; Marklin M; Heitmann JS; Kauer J; Osburg L; Zekri L; Bühring HJ; Mueller S; Hörner S; Baeuerle PA; Michaelson JS; Jung G; Salih HR
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
    Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CLEC12A plays an important role in immunomodulatory function and prognostic significance of patients with acute myeloid leukemia.
    Li Q; Liang C; Xu X; Zhang C; Cao W; Wang M; Jiang Z; Xing H; Yu J
    Leuk Lymphoma; 2022 Sep; 63(9):2136-2148. PubMed ID: 35481814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLT3-ITD DNA and mRNA levels in AML do not correlate with CD7, CD33 and CD123 expression.
    Soare DS; Radu E; Dumitru I; Popov VM; Bumbea H; Vlădăreanu AM
    J Cell Mol Med; 2020 Jul; 24(13):7675-7679. PubMed ID: 32460405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD33, CD96 and Death Associated Protein Kinase (DAPK) Expression Are Associated with the Survival Rate and/or Response to the Chemotherapy in the Patients with Acute Myeloid Leukemia (AML).
    Jiang Y; Xu P; Yao D; Chen X; Dai H
    Med Sci Monit; 2017 Apr; 23():1725-1732. PubMed ID: 28391288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.